IDH2 and glioblastoma: To determine whether the MGMT promoter status (determined by cutoff ≥30%) might correlated with other clinical features in IDH-mutant GBM, we compared the clinical features between cases with or without MGMT promoter methylation in cohort A. No significant difference was observed between unmethylated and methylated cases in terms of age, gender distribution, tumor type (primary or recurrent/secondary), extent of resection, KPS scores, or TMZ cycles (Table 2).